NCT07236411

Absolute Bioavailability Study of Cizutamig in Healthy Adult Participants

A Randomized, Double-blind, Phase 1 Study to Evaluate the Absolute Bioavailability of Cizutamig Following Single Intravenous or Subcutaneous Administration in Healthy Adult Participants

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 20 (estimated)
• Sponsor: Candid Therapeutics · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to determine the absolute bioavailability of SC administered cizutamig in healthy adult participants.

Detailed description

This is a randomized, double-blind, Phase 1 study designed to determine the absolute bioavailability of SC administered cizutamig in healthy adult participants. The study will enroll participants in SC and IV cohorts.

Conditions

• Healthy Participants Study

Interventions

Type	Name	Description
BIOLOGICAL	cizutamig	cizutamig will be dosed SC or IV according to the assigned cohort
OTHER	Placebo	placebo will be dosed IV or SC according to the assigned cohort

Timeline

• Start date: 2025-12-04
• Primary completion: 2026-03-01
• Completion: 2026-03-01
• First posted: 2025-11-19
• Last updated: 2025-12-26

Locations

1 site across 1 country: Australia